NCCN Guidelines for Patients® | Myelodysplastic Syndromes

72 NCCN Guidelines for Patients ® : Myelodysplastic Syndromes, 2018 Index Index acute myeloid leukemia (AML) 10, 19, 25–26, 31, 41, 43, 45–47, 55 anemia 13, 16–17, 24–25, 28–29, 42–45, 49–50 blood cell growth factor 29, 43–44, 51 blood stem cell 8–10, 13, 35–36, 39 bone marrow 6, 8, 10–13, 15–16, 18–21, 23, 29–33, 35–36, 39, 45–46, 51 chemotherapy 31–32, 35–37, 39, 43–48 chromosome 9–12, 19–20, 23–24, 33, 42–43, 50 clinical trial 31, 37–39, 42–49, 56 cytopenia 10, 12, 15–16, 23, 45 dysplasia 10–12, 16, 19 gene 9–10, 12, 19–21, 31, 33 hematopoietic cell transplant (HCT) 17, 31, 35 higher-risk MDS 25, 41, 44–48 high-intensity chemotherapy 31, 32, 46 immunosuppressive therapy (IST) 32 lower-risk MDS 25, 29, 33, 41–42, 44–45 low-intensity chemotherapy 31, 43–48 prognosis 20–21, 23, 26, 55 prognostic scoring 23–26 risk group 23–26, 35, 41, 55 risk score 23–26, 35, 55 serum EPO 15, 17, 29, 42–43, 50–51 side effect 28, 31–33, 35–38, 42–43, 46, 50–51, 56 subtype 10–13, 21, 23–25, 33, 41 supportive care 28, 39, 48, 49 transfusion 15, 17, 28–29, 33, 35, 41–43, 45, 49–50, 51

RkJQdWJsaXNoZXIy MTE3MTE1